{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078622","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.562405+00:00","generated_at":"2026-05-17T13:14:19.802331+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Outlook Therapeutics reports first LYTENAVA sales, $20.2M net loss for Q3 FY2025","bullets":["First commercial sales of LYTENAVA (bevacizumab gamma) in Germany and UK; $1.5M revenue recognized.","Net loss of $20.2M ($0.55 per share), compared to net loss of $0.89 per share in prior-year quarter.","Adjusted net loss of $15.8M ($0.44 per share), excluding $2.3M change in promissory notes and $2.0M warrant liability.","Cash and cash equivalents of $8.9M as of June 30, 2025.","FDA PDUFA goal date for ONS-5010 (bevacizumab-vikg) set for August 27, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078622","json":"https://secwatch.observer/filing/0001104659-25-078622.json","markdown":"https://secwatch.observer/filing/0001104659-25-078622.md","text":"https://secwatch.observer/filing/0001104659-25-078622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/0001104659-25-078622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925078622/tm2523462d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:14:19.802331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}